Survodutide quick reference
What is Survodutide?
Weekly injection that hits glucagon and GLP-1 receptors.
Studied for weight loss and fatty liver disease.
Not approved. Liver phase 3 trials are running.
How Survodutide works
Lowers appetite and food intake.
Adds a liver fat-burning pathway.
Doses rise over weeks to limit stomach effects.
What Survodutide is studied for
Lost 12.2% to 13.0% in 76 weeks.
MASH improved in 43% to 62%, vs 14% on placebo.
84% cut liver fat by 30% or more at 6 mg (48 weeks).
46-week phase 2 in adults with obesity.
Survodutide dosing protocol
| Study | Weekly amount |
|---|---|
| Phase 3 obesity, 76 weeks | Raised up to 3.6 mg or 6.0 mg (step-up plan not in the sources I checked) |
| Phase 2 obesity, 46 weeks | 0.6, 2.4, 3.6 or 4.8 mg (20 weeks raising, 26 weeks steady) |
| Phase 2 liver disease (MASH), 48 weeks | 2.4, 4.8 or 6.0 mg (24 weeks raising, 24 weeks steady) |
From the SYNCHRONIZE-1 NEJM 2026 abstract and registry (NCT06066515), the Lancet Diabetes & Endocrinology 2024 phase 2 paper (NCT04667377), and the NEJM 2024 MASH paper (NCT04771273). These are trial schedules. No label exists.
Label and trial amounts come from the sources below. Community amounts are what people report; they have not been tested.
Mixing
Common example. Add BAC water slowly, swirl, keep cold.
What the research found
SYNCHRONIZE-1: 725 adults with obesity, no diabetes, 76 weeks. Average body weight change (treatment-regimen analysis, which includes people who stopped early):
NEJM 2026 (SYNCHRONIZE-1, NCT06066515). The company's earlier headline of up to 16.6% used a different analysis (efficacy estimand, assumes the drug was taken as planned).
Survodutide community experience
What users report. Not tested in trials.
Positive reports
- Liver angle Obesity plus liver trials give it a bigger story.
- Dual-agonist talk Often compared with mazdutide and retatrutide.
- Easy to track Weight, waist and labs are simple to follow.
Negative & mixed
- Stomach upset GI effects can make people quit.
- Unverified vials Reports cannot confirm trial-grade material.
- Liver fat is not MASH Less liver fat does not mean fibrosis is healed.
Survodutide stacking
Same two receptors. Not studied together.
Retatrutide adds GIP. Not studied together.
Survodutide side effects & safety
Common
- Stomach effects: 81% (3.6 mg), 90% (6.0 mg), 48% placebo.
- Nausea: 66% vs 23% in the liver trial.
- Diarrhea: 49% vs 23% in the liver trial.
- Vomiting: 41% vs 4% in the liver trial.
- Mostly mild to moderate.
Less common
- No deaths in the 76-week trial.
- Serious events: 8% vs 7% placebo (liver trial).
- Safety beyond 76 weeks is unknown.
Precautions
- Pregnancy or breastfeeding: ask a doctor first.
- Insulin or sulfonylureas: sugar can drop.
- Advanced liver disease needs medical oversight.
- Severe belly pain or dehydration needs urgent care.
Our verdict on Survodutide
Solid phase 3 weight loss plus a liver story. Stomach effects limit how many stay on it.
Survodutide FAQ
Is survodutide approved?
No. It is still investigational.
How much weight did people lose?
About 12% to 13% at 76 weeks.
Does it treat fatty liver?
Phase 2 improved MASH. Phase 3 liver trials continue.
Sources
- Survodutide once weekly for the treatment of adults with obesity. N Engl J Med 2026 (SYNCHRONIZE-1), NCT06066515
- Survodutide for obesity, phase 2. Lancet Diabetes Endocrinol 2024, NCT04667377
- Sanyal AJ et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 2024, NCT04771273
- ClinicalTrials.gov NCT06066515, NCT06632444 (LIVERAGE, recruiting)
- Survodutide in adults with obesity and MASLD: SYNCHRONIZE-MASLD. Nat Med 2026 (PubMed 42252333)
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: phase 2 dose-finding trial. Lancet Diabetes Endocrinol 2024 (PubMed 38330987)